October 2005
Gut;Oct2005, Vol. 54 Issue 10, p1480
Academic Journal
The article presents information on several articles published in this journal. The article "Infliximab As Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study" explains the pattern of cytokine activation in Crohn's and ulcerative colitis (UC). It is reported that anti-tumour necrosis factor therapy would not be useful in UC. The article "Statins and the Risk of Colorectal Cancer," presents a case study. It is reported that colorectal cancer screening is being instituted but a strategy of chemoprevention may have a greater impact.


Related Articles

  • Efficacy of anti-TNF-alpha monoclonal antibodies in inflammatory bowel disease treatment. Deleporte, Amélie; Viennot, Stéphanie; Dupont, Benoît; Gilletta, Cyrielle; Allaire, Manon; Prévost, Frédérique; Reimund, Jean-Marie // International Journal of Interferon, Cytokine & Mediator Researc;2013, Vol. 5, p11 

    Pathogenesis of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), continues to drive basic research to better decrypt their causal factor(s). Several key mediators involved in IBD pathogenesis have been identified and are considered as potential...

  • CORRECTION.  // Gut;Nov2004, Vol. 53 Issue 11, p1722 

    Several corrections to the articles including "Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor antibody treatment," by S. J. Connor, "Morphological characterisation of Crohn's disease fistulae," by F. Bataille, and "Divergent patterns...

  • Downregulation of CPI-17 contributes to dysfunctional motility in chronic intestinal inflammation model mice and ulcerative colitis patients. Ohama, Takashi; Hori, Masatoshi; Fujisawa, Masahiko; Kiyosue, Masaharu; Hashimoto, Masaki; Ikenoue, Yuka; Jinno, Yoshio; Miwa, Hiroto; Matsumoto, Takayuki; Murata, Takahisa; Ozaki, Hiroshi // Journal of Gastroenterology;2008, Vol. 43 Issue 11, p858 

    Chronic intestinal inflammation is frequently accompanied by motility disorders. We previously reported that proinflammatory cytokines, such as tumor necrosis factor α and interleukin (IL)-1β downregulate CPI-17, an endogenous inhibitor of serine/threonine protein phosphatase in...

  • Anti-Tumour Necrosis Factor Therapy for Ulcerative Colitis: Evidence to Date. Thukral, Chandrashekhar; Cheifetz, Adam; Peppercorn, Mark A. // Drugs;2006, Vol. 66 Issue 16, p2059 

    Infliximab, the chimeric monoclonal antibody directed against tumour necrosis factor (TNF)-α, has profoundly changed therapy for Crohn's disease (CD). However, for ulcerative colitis (UC), before the publication of ACT 1 and ACT 2 (Active Ulcerative Colitis Trials 1 and 2), there were only a...

  • Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. Papa, Alfredo; Mocci, Giammarco; Bonizzi, Michele; Felice, Carla; Andrisani, Gianluca; De Vitis, Italo; Guidi, Luisa; Gasbarrini, Antonio // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1575 

    With the increasingly widespread use of the anti-tumor necrosis factor-α agent infliximab for the treatment of Crohn's disease and ulcerative colitis, there have been some concerns raised about the potential consequences of such therapy in particular clinical settings. In this review, we...

  • Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Vivinus-Nébot, M.; Frin-Mathy, G.; Bzioueche, H.; Dainese, R.; Bernard, G.; Anty, R.; Filippi, J.; Saint-Paul, M. C.; Tulic, M. K.; Verhasselt, V.; Hébuterne, X.; Piche, T. // Gut;May2014, Vol. 63 Issue 5, p744 

    Objective To determine the role of colonic barrier defects and low-grade inflammation in irritable bowel syndrome (IBS)-like symptoms in quiescent inflammatory bowel disease (IBD). Design Caecal biopsies were collected from 51 IBS, 49 quiescent IBD (31 Crohn's disease (CD) and 18 ulcerative...

  • Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. Andrisani, G.; Guidi, L.; Papa, A.; Armuzzi, A. // European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 7, p890 

    Inflammatory bowel disease, Crohn's disease and ulcerative colitis, are immune- mediated disorders of unknown etiology that primarily affect the gastrointestinal tract. In addition, other organ systems can be involved such as joint/bones, skin, eyes, hepatobiliary tract, lungs and kidney....

  • BIOLOGICS IN INFLAMMATORY BOWEL DISEASE: HOW MUCH PROGRESS HAVE WE MADE? Sandborn, W. J.; Faubion, W. A. // Gut;Sep2004, Vol. 53 Issue 9, p1366 

    The article focuses on the progress made in the treatment of inflammatory bowel disease with biologic therapies, concentrating primarily on the tumor necrosis factor (TNF) inhibitors infliximab, etanercept, adalirnumab, CDP87O, CDP571 and onercept, and on the selective adhesion molecule...

  • Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Kakuta, Y.; Kinouchi, Y.; Negoro, K.; Takahashi, S.; Shimosegawa, T. // Gut;Oct2006, Vol. 55 Issue 10, p1527 

    The article presents a letter entitled "Association study of TNFSF 15 polymorphisms in Japanese patients with inflammatory bowel disease," by Y. Kakuta, Y. Kinouchi and K. Negoro published within the issue. The study focuses on the role of tumor necrosis factor superfamily 15 in patients with...


Read the Article


Sign out of this library

Other Topics